Kidney Failure Clinical Trials 2023

What are the top hospitals conducting kidney failure research?

When it comes to the battle against kidney failure, top hospitals across the United States are leading the charge in clinical trials and innovative research. In Cleveland, Ohio, the renowned Cleveland Clinic is currently conducting six active trials focused on kidney failure. While their history of kidney failure studies may be more recent with only two recorded trials thus far, they have wasted no time in making strides since their first trial in 2019. Vanderbilt University Medical Center in Nashville has also emerged as a key player in this field. With four ongoing clinical trials and an impressive total of 27 completed studies dating back to their inaugural trial in 1998, they have long been committed to advancing knowledge and treatment options for patients suffering from kidney failure.

Notably contributing to this cause is Clinical Advancement Center (CAC), PLLC located in San Antonio. This emerging center boasts four active clinical trials dedicated to finding breakthroughs for kidney failure patients while having conducted just two previous investigations since recording its first trial in 2014. The University of Florida's medical campus based in Gainesville similarly highlights its dedication through three ongoing clinical tests aimed at addressing kidney failure cases while adding up three different studies performed throughout these years from starting it's pioneering investigation on such conditions way back until2006.

Meanwhile, Emory University Hospital situated amidst Atlanta’s bustling medical scene joins the ranks with its own trio of active renal failure trials alongside three previously held studies that began shaping pathways towards progress from as early as2003.These top hospitals collectively demonstrate that significant efforts are being made nationwide not only to understand but also combat this challenging condition.

With each new study undertaken and every milestone achieved by these institutions comes renewed hope for individuals grappling with or at risk of developing kidney failure. Through tireless research and unwavering commitment, these hospitals continually strive toward improving treatments and quality of life for patients everywhere who are affected by this debilitating condition

Which are the best cities for kidney failure clinical trials?

In the realm of kidney failure clinical trials, several cities emerge as leading hubs for research and innovation. Houston, Texas takes the lead with 27 active trials, investigating promising treatments like MK-2060, Cohort 2, and Avelumab (MSB0010718C). Following closely behind is Los Angeles, California with 21 ongoing studies focusing on interventions such as Avelumab (MSB0010718C), MK-2060, and CIN-107. Chicago also makes its mark in this field with 19 active trials exploring options like Cohort 2 and Finerenone (BAY94-8862). These cities offer a wealth of opportunities for individuals battling kidney failure to participate in cutting-edge clinical trials that pave the way for improved care and potential breakthroughs.

Which are the top treatments for kidney failure being explored in clinical trials?

Kidney failure research is paving the way for potential breakthroughs, with several promising treatments currently being explored in clinical trials. MK-2060 has taken center stage, with two active trials and a total of five kidney failure trials since its introduction in 2019. Another contender making waves is semaglutide, showing promise with two ongoing trials and one all-time trial dedicated to kidney failure since its listing in 2023. Finally, empagliflozin enters the fray with two active trials and a modest but growing history of two kidney failure studies since it was first listed in 2018. These exciting developments bring hope to patients as researchers strive to find innovative solutions for managing and treating kidney failure globally.

What are the most recent clinical trials for kidney failure?

Recent clinical trials offer promising prospects for individuals with kidney failure. One notable trial focuses on an intervention group aiming to address the underlying causes and improve treatment outcomes. Another study examines the efficacy of a specific regimen tailored for patients with chronic kidney disease, offering potential advancements in managing this condition. Additionally, research explores the benefits of incorporating alkalizing fruit and vegetables into dietary plans as a complementary approach to support renal function. Furthermore, LY3437943 shows promise as a therapeutic option through its inclusion in phase 2 clinical trials. Lastly, Renal Autologous Cell Therapy (REACT) is being investigated in phase 1 trials for its potential to revolutionize treatment options by utilizing autologous cells derived from the patient's own body. With these innovative studies underway, there is renewed hope for improved interventions against kidney failure.

What kidney failure clinical trials were recently completed?

Several recent clinical trials have brought us closer to advancements in the treatment of kidney failure. Merck Sharp & Dohme LLC completed a trial for MK-2060 in May 2022, showcasing potential therapeutic options. Duke University's trial on Patiromer Oral Powder Product concluded successfully in June 2019, while Wake Forest University Health Sciences' study on Hemodialysis also reached completion during that same month. Notably, Merck Sharp & Dohme Corp.'s trial for MK-2060 wrapped up in April 2019 alongside Raymond Chung's glecaprevir/pibrentasvir treatment investigation. These significant findings pave the way for improved management strategies and renewed hope for individuals grappling with kidney failure.